Non-invasive transplant TAI Diagnostics specializes in a non-invasive, highly sensitive diagnostic test to monitor health of transplanted organs, indicating potential collaboration opportunities with transplant centers, hospitals, and organ procurement organizations seeking monitoring solutions.

Early-stage funding With a total funding of 29M and a recent Series A extension of 10M completed in 2018, there may be ongoing capital needs or opportunities to engage with investors or funding rounds for expansion, clinical trials, or payer adoption efforts.

Strategic partnerships Past collaborations with United Therapeutics and Unither Bioélectronique suggest openness to pharma and biotech partnerships; identify similar potential partners in organ transplantation, regenerative medicine, or related diagnostic ecosystems.

Limited scale Small company size (11-50 employees) and revenue under 1 million indicate a need for channel partners, distributors, or accelerate co-development deals to scale market access and clinical adoption more rapidly.

Healthcare tech fit Technical stack (WordPress, PHP, analytics) signals potential for digital marketing and data integration capabilities; propose value propositions around streamlined vendor-neutral data capture, remote monitoring integration, and payer/clinical workflow compatibility.